MedPath

Prophylaxis of Ileostomy Closure Site Hernia by Placing Mesh

Phase 4
Conditions
Loop Ileostomy Closure
Interventions
Procedure: MESH
Procedure: NO MESH
Radiation: Post-operative Imaging
Radiation: Pre-operative Imaging
Other: Blood Test and C-reactive protein at 4th day
Registration Number
NCT02226887
Lead Sponsor
Hospital Universitari Vall d'Hebron Research Institute
Brief Summary

Design Prospective , randomized, parallel phase IV.

Objectives Main objective

* Evaluate the effectiveness of the placement of a resorbable mesh in the prevention of incisional hernia of the abdominal wall at the site of a loop ileostomy when it is "closed " to rebuild the intestinal transit. The effectiveness evaluation is done by tracking with scheduled patient visits for 12 months, assessing the physical examination the presence or absence of an incisional hernia and an abdominal tomography at the end of the 12 months .

Secondary objectives Comparison of complications(morbidity and mortality) to assess safety and tolerability of the placement of the mesh described .

Detailed Description

Experimental: Reinforcement with Absorbable Mesh Closure of the ileostomy closure incision is reinforced with insertion of a rectangular segment (1 cm wide and the length corresponding to the incision) of a prosthetic commercially available GORE® BIO-A® Tissue Reinforcement prosthesis (W. L. Gore \& Associates, Flagstaff, Arizona, USA) mesh. The BIO-A® prosthesis is inserted using a "sandwich" method between the edges of the incision and maintained in situ with a continuous polydioxanone (PDS) suture following a suture length to wound length (SL:WL) ratio of 4:1.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
120
Inclusion Criteria
  • Patients undergoing a loop ileostomy closure
Exclusion Criteria
  • Patients under 18
  • Pregnancy and Lactation
  • Patients allergic to polyglycolic / trimethylene carbonate
  • Carrier of prosthetic mesh in the ostomy
  • Patients presenting midline hernia.
  • Patients affected by inflammatory bowel disease

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
NO MESHPost-operative Imaging-
NO MESHPre-operative Imaging-
MESHPre-operative Imaging-
MESHMESH-
MESHPost-operative Imaging-
MESHBlood Test and C-reactive protein at 4th day-
NO MESHBlood Test and C-reactive protein at 4th day-
NO MESHNO MESH-
Primary Outcome Measures
NameTimeMethod
Eventration1 year

Measured by clinical checks at 1 - 6 - 12 months and Abdominal tomography 1 year after the surgery.

Secondary Outcome Measures
NameTimeMethod
Iatrogenic problems30 days after surgery

Damage to structures such as ureters, bowel loops artery / iliac vein ....

* This is a Surgical and Clinical measure supported by image if necessary.

* All the morbidity problems are reported independently.

Cardiac complications30 days after surgery

acute myocardial infarction, angor pectoris , atrial fibrillation, acute pulmonary edema

* This is a Clinical measure supported by more specific tests if necessary.

* All the morbidity problems are reported independently.

* Cardiologist report will be required for including this items

Gastrointestinal complications30 days after surgery

Liver failure, gastrointestinal bleeding, severe malnutrition, ...

* This is a Clinical measure supported by blood test and further test if necessary

* All the morbidity problems are reported independently.

Local complications30 days after surgery

Hematoma, seroma, evisceration

* This is a Clinical measure

* All the morbidity problems are reported independently

Occlusive problems30 days after surgery

Intestinal occlusion, Anastomotic stenosis, Prolonged ileus(\>5days),....

* This is a Clinical measure supported by image if necessary

* All the morbidity problems are reported independently.

* 1 patient can suffer a prolonged ileus and Anastomotic stenosis and both will be reported.

Bleeding problems30 days after surgery

Hemoperitoneum, abdominal hematoma,anastomotic bleeding ....

* This is a Clinical measure supported by image if necessary.

* All the morbidity problems are reported independently.

* The amount of blood loss won't be specified

Nephro-urinary complications30 days after surgery

Acute urinary retention, Acute renal failure, cystitis, pyelonephritis ...

* This is a Clinical measure supported by more specific tests if necessary.

* All the morbidity problems are reported independently.

Impaired healing30 days after surgery

Anastomotic leak rate , intestinal fistula , vesical fistula, peritonitis...

* This is a Clinical measure always supported by image tests.

* All the morbidity problems are reported independently.

Neurological complications30 days after surgery

Disorientation, cerebral vascular accident, ...

* This is a Clinical measure.

* All the morbidity problems are reported independently.

* Neurologist report will be required beyond disorientation.

Respiratory complications30 days after surgery

Pneumonia, Atelectasis, Pulmonary embolism, Respiratory distress syndrome ...

* This is a Clinical measure always supported by image .

* All the morbidity problems are reported independently.

Vascular Complications30 days after surgery

Deep venous thrombosis, phlebitis, thrombophlebitis, ...

* This is a Clinical measure supported by more specific test if necessary .

* All the morbidity problems are reported independently

Local infection30 days after surgery

Superficial, deep, body-cavity

* This is a Clinical measure supported by image if necessary

* All the morbidity problems are reported independently

Hospital stayDays

Hospital stay since surgery is done

Trial Locations

Locations (1)

Hospital General Universitario Vall d´Hebron

🇪🇸

Barcelona, Spain

© Copyright 2025. All Rights Reserved by MedPath